Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
James Karrels, insider at MacroGenics

James Karrels Insider Information

CFO of MacroGenics
Mr. Karrels, Senior Vice President, Chief Financial Officer and Corporate Secretary, joined us in May 2008 and has over 25 years of experience in finance, with a significant portion of that time working for, or on behalf of, life sciences companies. Prior to joining us, he served as Executive Director of Finance at Jazz Pharmaceuticals, Inc., where he was responsible for the company’s financial planning and analysis and investor relations activities. Prior to joining Jazz Pharmaceuticals, Mr. Karrels was in the Global Healthcare Investment Banking Group at Merrill Lynch, serving most recently as a Director. Mr. Karrels holds an M.B.A. from Stanford University and a B.B.A. from the University of Notre Dame.

What is James Karrels' net worth?

The estimated net worth of James Karrels is at least $577,245.76 as of June 15th, 2022. Mr. Karrels owns 191,776 shares of MacroGenics stock worth more than $577,246 as of June 28th. This net worth evaluation does not reflect any other investments that Mr. Karrels may own. Additionally, Mr. Karrels receives an annual salary of $577,900.00 as CFO at MacroGenics. Learn More about James Karrels' net worth.

How old is James Karrels?

Mr. Karrels is currently 55 years old. There are 6 older executives and no younger executives at MacroGenics. The oldest executive at MacroGenics is Dr. Scott Koenig M.D., Ph.D., Pres, CEO & Director, who is 70 years old. Learn More on James Karrels' age.

What is James Karrels' salary?

As the CFO of MacroGenics, Inc., Mr. Karrels earned a total compensation package of $1,254,970.00 in 2020. Mr. Karrels earned a salary of $431,496.00, options awards of $641,133.00, non-equity compensation of $173,791.00, and other compensation of $8,550.00.There are 2 executives that earn more than Mr. Karrels. The highest earning executive at MacroGenics is Dr. Scott Koenig M.D., Ph.D., Pres, CEO & Director, who commands a salary of $954,140.00 per year. Learn More on James Karrels' salary.

How do I contact James Karrels?

The corporate mailing address for Mr. Karrels and other MacroGenics executives is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. MacroGenics can also be reached via phone at (301) 251-5172 and via email at [email protected] Learn More on James Karrels' contact information.

Has James Karrels been buying or selling shares of MacroGenics?

Over the course of the past ninety days, James Karrels has bought $98,800.00 in MacroGenics stock. As an example of a recent trade by , 0 shares of the stock in a transaction that occurred on Tuesday, June 28th. Learn More on James Karrels' trading history.

Who are MacroGenics' active insiders?

MacroGenics' insider roster includes James Karrels (CFO), and Thomas Spitznagel (SVP). Learn More on MacroGenics' active insiders.

Are insiders buying or selling shares of MacroGenics?

During the last year, MacroGenics insiders bought shares 4 times. They purchased a total of 740,000 shares worth more than $14,238,800.00. During the last year, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 5,000 shares worth more than $125,050.00. The most recent insider tranaction occured on June, 15th when CFO James Karrels bought 40,000 shares worth more than $98,800.00. Insiders at MacroGenics own 7.9 % of the company. Learn More about insider trades at MacroGenics.

Information on this page was last updated on 6/15/2022.

James Karrels Insider Trading History at MacroGenics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/15/2022Buy40,000$2.47$98,800.00191,776View SEC Filing Icon  
3/22/2021Sell15,000$33.00$495,000.00View SEC Filing Icon  
3/5/2018Sell5,000$31.00$155,000.00View SEC Filing Icon  
See Full Table

James Karrels Buying and Selling Activity at MacroGenics

This chart shows James Karrels's buying and selling at MacroGenics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

MacroGenics Company Overview

MacroGenics logo
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $3.01
Low: $2.96
High: $3.23

50 Day Range

MA: $4.37
Low: $2.25
High: $8.20

2 Week Range

Now: $3.01
Low: $2.13
High: $29.16

Volume

588,459 shs

Average Volume

897,232 shs

Market Capitalization

$184.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.17
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.